Day: ខែ​កក្កដា 31, 2025

TOKYO, July 31, 2025 – (JCN Newswire via SeaPRwire.com) – TANAKA PRECIOUS METAL GROUP Co., Ltd. (Headquarters: Chuo-ku, Tokyo; Group CEO: Koichiro Tanaka) has decided to enter into a business partnership with JEPLAN, INC. (Headquarters: Kawasaki City, Kanagawa; Representative Director, President, and Chief Executive Officer: Masaki Takao; hereinafter “JEPLAN”) to reduce CO₂ emissions and promote the recycling organic materials in the precious metal recovery processes of TANAKA PRECIOUS METAL TECHNOLOGIES Co., Ltd., a company engaged in precious metals business.This initiative represents a collaboration between TANAKA, committed to advancing a circular economy in the precious metals field, and JEPLAN, which has been pursuing similar goals in the plastics field, with both companies aiming to achieve a decarbonized, circular society.TANAKA’s Initiatives Thus Far for Realizing a Circular SocietySince its founding in 1885, TANAKA has been a leader in the precious metals industry, actively engaged in recycling thes…

KARIYA, JAPAN, July 31, 2024 – (JCN Newswire via SeaPRwire.com) – DENSO, a leading mobility supplier, today announced global financial results for the first quarter, ending June 30, 2025, of its fiscal year, ending March 31, 2026:Consolidated revenue totaled 1,754.1 billion yen (US$11.7 billion), remaining consistent with the previous year.Consolidated operating profit totaled 107.2 billion yen (US$0.7 billion), an 11.1 percent decrease from the previous year.Consolidated profit attributable to owners of the parent company totaled 79.3 billion yen(US$0.5 billion), a 16.1 percent decrease from the previous year.“Revenue in the first quarter remained consistent with the previous year, driven by a strong increase in vehicle sales in Japan, despite a decline in revenue due to the impact of the strong yen.” said Yasushi Matsui, CFO, Executive Vice President and member of the Board of Directors of DENSO CORPORATION.“In this fiscal year, we forecast 7,200.0 billion yen (US$48.2 billion) in revenue and 675.0 billion …

TOKYO, Japan, July 31, 2025 – (JCN Newswire via SeaPRwire.com) –Honda Motor Co., Ltd. today launched a teaser page on its company website to share information on the all-new Prelude, which is scheduled to go on sale in September 2025.The all-new Prelude is a specialty sports model which represents the unrelenting Honda sports mindset, carrying forward the “joy of driving” into the electrified era, while also pursuing environmental performance and everyday usability.All-New Prelude Teaser Page: https://www.honda.co.jp/PRELUDE/new/All-new PreludeOverview of all-new PreludeGrand Concept: “Unlimited Glide” — Endless driving pleasure & Extraordinary experience —Inspired by the image of gliders soaring freely and boundlessly through the open sky, Honda developed the all-new Prelude under the grand concept of “Unlimited Glide,” striving for a vehicle that evokes the uplifting sensation of gliding gracefully through the air and extraordinary experience that people do not have in their everyday lives.Like a glider…

Developing dual-use UAVs for civil and defense applicationsAutomating the transport of heavy cargo with MHI’s multi-purpose medium-sized UAVAccelerating the transport of medications using a VTOL (vertical take-off and landing) UAV capable of flying long distances at high speedTOKYO, July 31, 2025 – (JCN Newswire via SeaPRwire.com) – Mitsubishi Heavy Industries, Ltd. (MHI) participated in a practical training exercise held on July 17 at the Japan Ground Self-Defense Force (JGSDF) Asaka Garrison (Nerima-ku, Tokyo), aimed at improving response capabilities in the event of an earthquake centered on the Tokyo metropolitan area. The training was conducted by the JGSDF Eastern Army in cooperation with local governments, with MHI joining at the request of the Japan UAS Industrial Development Association (JUIDA). MHI conducted training to transport relief supplies to isolated disaster victims using its medium-sized multirotor uncrewed aerial vehicle (hereinafter “medium-sized UAV”) currently being developed by its Com…

– Data Showed LEQEMBI Slowed Clinical Decline by 1.75 Points on CDR-SB at Four Years Compared to the Natural History of Alzheimer’s Disease- 56% of Patients with Low Tau Continued to Demonstrate Improved Cognitive and Daily Living Function at Four YearsTOKYO and CAMBRIDGE, Mass., July 31, 2025 – (JCN Newswire via SeaPRwire.com) – Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”)and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher,“Biogen”) announced today that the latest findings demonstrating the benefits of continuous treatment with lecanemab-irmb (U.S. brand name: LEQEMBI®), an anti-amyloid beta (AB) protofibril* antibody for the treatment of early Alzheimer’s disease (AD), were presented at the Alzheimer’s Association International Conference(AAIC) 2025, held in Toronto, Canada, and virtually. Only lecanemab fights AD in two ways – targeting both amyloid plaque and protofibrils*, which can impact tau downstream.Four Years of Lecanemab Therapy…

TOKYO and CAMBRIDGE, Mass., July 31, 2025 – (JCN Newswire via SeaPRwire.com) – Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”)and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher,“Biogen”) announced today that results on investigational maintenance therapy with subcutaneous autoinjector (SCAI) of lecanemab-irmb (U.S. brand name: LEQEMBI®), an anti-amyloid beta (AB) protofibril* antibody for the treatment of early Alzheimer’s disease (AD), were presented at the Alzheimer’s Association International Conference(AAIC) 2025, held in Toronto, and virtually. Only lecanemab fights AD in two ways—targeting both protofibrils and plaque, which can impact tau accumulation downstream.Importance of Ongoing Treatment and SC Development ProgramDue to the reaccumulation of AD biomarkers and return to placebo rate of decline after therapy is stopped1, Eisai is investigating a new lecanemab SC maintenance treatment option following 18 months of IV therapy so pati…

Santa Clara, CA, July 29, 2025, (ACN Newswire via SeaPRwire.com) – Meshy.ai, the world’s leading AI-powered 3D content generation platform, has launched the Meshy 5 Preview, offering early access to the next generation of AI 3D model generator. Built on the strong foundation of Meshy 4, this preview version introduces smarter generation tools, enhanced image alignment, sharper geometry, and over 500 new animations—empowering creators to build faster, cleaner, and more creatively than ever before.Trusted by 3 Million Creators – The Platform of Choice for Game DevelopersWith over 30 million 3D assets generated and a community of more than 3 million creators, Meshy has become the go-to AI platform for game developers, VFX artists, and 3D content professionals worldwide. Recognized by Andreessen Horowitz (a16z) as the only 3D tool featured in its list of “Most Popular AI Tools Among Game Developers,” Meshy is redefining how digital worlds are built—with speed, accuracy, and creative control.What’s New in Meshy 5 …

TOYOTA CITY, July 30, 2025 – (JCN Newswire via SeaPRwire.com) – Toyota Motor Corporation announces its sales, production, and export results for June 2025 as well as the cumulative total from January to June 2025, including those for subsidiaries Daihatsu Motor Co., Ltd. and Hino Motors, Ltd.For more details, please see the link below (detailed data).Click here for detailed sales, production, and export results (“Detailed data (Excel)”)URL https://global.toyota/en/company/profile/production-sales-figures/202506.html  Copyright 2025 JCN Newswire via SeaPRwire.com.

TOKYO and CAMBRIDGE, Mass., July 31, 2025 – (JCN Newswire via SeaPRwire.com) – Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito,“Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A.Viehbacher, “Biogen”) announced today that the two-year real-world study in the U.S of lecanemab (generic name, product name: LEQEBMI®), an anti-AB protofibril* antibody, was presented at the Alzheimer’s Association International Conference (AAIC) 2025, held in Toronto, Canada and virtually. Only lecanemab fights AD in two ways– targeting both amyloid plaque and protofibrils*, which can impact tau downstream.Lecanemab received traditional approval in the U.S. in July 2023 for the treatment of early Alzheimer’s disease (AD). This retrospective study was conducted to investigate the actual state of real-world clinical treatment with lecanemabat 15 medical centers in the U.S., with a final report scheduled for late in the third quarter of Eisai’s fiscal year ending March 31…